KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares

CSNasdaq (XNAS)·USD

Identity

Security key: 17777
Ticker: KNSA
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2018-05-24
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: KNSA

Detail

Enriched 2026-08-14 20:47

Market cap: $6,097,576,615.95
Shares outstanding (class): 48,289,273
Shares outstanding (weighted): 78,024,013
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 366
Location: LONDON
Homepage: https://www.kiniksa.com
Description: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Market cap and share counts drift.

Funds holding this security

56 funds · 57 positions · $261.89M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$62.09M	0.00%	1,289,409 NS	TICKER
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$45.82M	0.03%	951,548 NS	TICKER
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$25.76M	0.07%	534,982 NS	TICKER
Victory Trivalent International Small-Cap Fund Victory Portfolios	—	$16.02M	0.37%	332,730 NS	TICKER
Fidelity U.S. Equity Central Fund Fidelity Central Investment Portfolios LLC	—	$13.72M	0.07%	285,000 NS	TICKER
Fidelity Advisor New Insights Fund Fidelity Contrafund	—	$11.24M	0.05%	233,400 NS	TICKER
Fidelity Contrafund Fidelity Contrafund	—	$9.37M	0.01%	194,676 NS	TICKER
Fidelity Fund Fidelity Hastings Street Trust	—	$9.02M	0.11%	187,400 NS	TICKER
VIP Health Care Portfolio Variable Insurance Products Fund IV	—	$7.22M	0.72%	150,000 NS	TICKER
Fidelity Series Opportunistic Insights Fund Fidelity Contrafund	—	$6.46M	0.05%	134,100 NS	TICKER
MFS New Discovery Series MFS VARIABLE INSURANCE TRUST	—	$5.19M	0.73%	107,710 NS	TICKER
Driehaus Micro Cap Growth Fund Driehaus Mutual Funds	—	$4.70M	1.03%	97,649 NS	TICKER
VIP Contrafund Portfolio Variable Insurance Products Fund II	—	$4.43M	0.02%	92,000 NS	TICKER
VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS	—	$3.81M	0.04%	79,078 NS	TICKER
Fidelity Enhanced Small Cap ETF Fidelity Covington Trust	FESM	$3.70M	0.09%	76,836 NS	TICKER

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

This match is a candidate, not a mapping. N-PORT tickers are filer-entered free text and collide with delisted and foreign symbols. Only 13% of positions carry a ticker at all. Good enough to ask which funds report holding a symbol; not good enough to build exposure reporting on. Prefer the ISIN-resolved link, which is marked FIGI_COMPOSITE.

Funds holding this security

Identifiers

master.security_identifier

TICKERKNSA
CIK0001730430
ISINGB00BRXB0C07
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Kiniksa is a biopharmaceutical company focused on developing and commercializing therapies for inflammatory diseases, fitting the pharmaceuticals industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.